Faculty Bibliography

Introduction: Recent work has demonstrated head motion contributes to artifactual differences in resting-state fMRI (R-fMRI) measures (Power et al., 2012a;Satterthwaite et al., 2012;Van Dijk et al., 2012). Here we explored how a broad array of R-fMRIbased intrinsic brain function measures are affected by head motion, and how such sensitivities and their test-retest (TRT) reliabilities are impacted by various motion correction strategies. Methods: After preprocessing publicly released developmental, young adult and TRT datasets, the following strategies were applied to correct head motion effects: regressing out 6 head motion parameters (Traditional 6), regressing out autoregressive models (Friston et al., 1996) (Friston 24), regressing out voxelspecific head motion regressors (Voxel-Specific 12), and data scrubbing at framewise displacement (FD) > 0.2 or 0.5mm. We then explored head motion effects and TRT reliability on amplitude of low frequency fluctuation (ALFF), fractional ALFF (fALFF), regional homogeneity, voxel-mirrored homotopic connectivity, and functional connectivity of medial prefrontal cortex. Results: As previously suggested, head motion effects are stronger in developmental than adult data (Fig. 1 vs. Fig. 2). Among the measures, fALFF is least affected by head motion. Among head motion correction strategies, scrubbing at FD > 0.2 mm (Power et al., 2012b) cleared the most motion effect while creating artificial head motion effect in fALFF due to destruction of temporal structure. Scrubbing at FD > 0.2mm also diminished TRT reliability dramatically (Fig. 3); some subjects varied markedly in the number of time points excluded across sessions (e.g., (Figure Presented) 150 vs. 37). Importantly, head motion effects remained after all correction strategies (Figs. 1, 2) suggesting taking subject head motion into account at the group level is still necessary. Regressing out mean FD slightly decreased TRT reliability but preserved its structure (Fig. 4). Conclusion: Results suggest that head motion effects extend to all metrics when studying hyperkinetic populations. We suggest caution when using stringent scrubbing (e.g. FD > 0.2mm as recommend by Power et al. 2012b), as test-retest reliability can be compromised and frequency metrics made immeasurable. Correction for inter-individual differences in motion at the grouplevel appears to be necessary regardless of individual subject correction strategy

In recent years, there has been growing enthusiasm that functional magnetic resonance imaging (MRI) could achieve clinical utility for a broad range of neuropsychiatric disorders. However, several barriers remain. For example, the acquisition of large-scale datasets capable of clarifying the marked heterogeneity that exists in psychiatric illnesses will need to be realized. In addition, there continues to be a need for the development of image processing and analysis methods capable of separating signal from artifact. As a prototypical hyperkinetic disorder, and movement-related artifact being a significant confound in functional imaging studies, ADHD offers a unique challenge. As part of the ADHD-200 Global Competition and this special edition of Frontiers, the ADHD-200 Consortium demonstrates the utility of an aggregate dataset pooled across five institutions in addressing these challenges. The work aimed to (1) examine the impact of emerging techniques for controlling for "micro-movements," and (2) provide novel insights into the neural correlates of ADHD subtypes. Using support vector machine (SVM)-based multivariate pattern analysis (MVPA) we show that functional connectivity patterns in individuals are capable of differentiating the two most prominent ADHD subtypes. The application of graph-theory revealed that the Combined (ADHD-C) and Inattentive (ADHD-I) subtypes demonstrated some overlapping (particularly sensorimotor systems), but unique patterns of atypical connectivity. For ADHD-C, atypical connectivity was prominent in midline default network components, as well as insular cortex; in contrast, the ADHD-I group exhibited atypical patterns within the dlPFC regions and cerebellum. Systematic motion-related artifact was noted, and highlighted the need for stringent motion correction. Findings reported were robust to the specific motion correction strategy employed. These data suggest that resting-state functional connectivity MRI (rs-fcMRI) data can be used to characterize individual patients with ADHD and to identify neural distinctions underlying the clinical heterogeneity of ADHD.

Background: Tau pathology is involved in multiple neurodegenerative disorders, for example in Alzheimer's disease, Parkinson's disease, and Frontotemporal dementia (FTD). Tau is a neuronal protein that binds microtubules and is thought to be involved in the stabilization of microtubules. Over 50 different mutations within the MAPT gene, the gene encoding for Tau, have been associated with inherited FTD. FTD is thought to involve deficits in the communication between neurons and in the mechanisms neuronal adaptation to experience, synaptic plasticity. The role of Tau in mechanisms of synaptic plasticity is not well-understood. To address this gap in the field, we have investigated synaptic plasticity and behavior in P301L mice, a mouse model for tau pathology that over-expresses human Tau protein carrying an inherited human mutation. Methods: Long-lasting forms of plasticity, late-phase long term potentiation (L-LTP) were examined in P301L (JNPL3) mice and age-matched controls by measuring field excitatory postsynaptic potentiation (fEPSP) in the CA1 hippocampal region after high frequency electrophysiological stimulation. Two behaviors associated with GABAergic function were assayed, prepulse inhibition of startle response (PPI) and susceptibility to epileptic seizures. GABAergic interneurons were stained using two markers; paravalbumin and somatostatin. Results: By examining long-lasting forms of plasticity in aged (>18 months old) in hippocampal brain slices we found surprisingly enhanced L-LTP in P301L mice compared to age-matched controls. The enhanced L-LTP in P301L slices was rescued by treatment with a GABA agonist, Zolpidem. These results suggest a loss of GABAergic neurons in P301L mice. Next we examined PPI and susceptibility to epileptic seizures in P301L and control mice. We found an altered PPI response and differences in epileptic seizures grades. Finally, we stained GABAergic interneurons in the hippocampus using two markers that identify GABAergic cell types showing a decrease in GABAergic neurons in the hippocampal CA1 region. Conclusions: Our results suggest that GABAergic interneurons are more vulnerable to molecular lesions caused by pathological Tau, which may result in the selective loss of hippocampal GABAergic interneurons. The molecular mechanisms involved in this specific GABAergic loss remains to be resolved, but may help to explain the pathophysiological symptoms of diseases like FTD, which involve altered Tau function

Although evidence is accumulating that diabetes mellitus is an important risk factor for sporadic Alzheimer's disease (AD), the mechanisms by which defects in insulin signaling may lead to the acceleration of AD progression remain unclear. In this study, we applied streptozotocin (STZ) to induce experimental diabetes in AD transgenic mice (5XFAD model) and investigated how insulin deficiency affects the beta-amyloidogenic processing of amyloid precursor protein (APP). Two and half months after 5XFAD mice were treated with STZ (90 mg/kg, i.p., once daily for two consecutive days), they showed significant reductions in brain insulin levels without changes in insulin receptor expression. Concentrations of cerebral amyloid-beta peptides (Abeta40 and Abeta42) were significantly increased in STZ-treated 5XFAD mice as compared with vehicle-treated 5XFAD controls. Importantly, STZ-induced insulin deficiency upregulated levels of both beta-site APP cleaving enzyme 1 (BACE1) and full-length APP in 5XFAD mouse brains, which was accompanied by dramatic elevations in the beta-cleaved C-terminal fragment (C99). Interestingly, BACE1 mRNA levels were not affected, whereas phosphorylation of the translation initiation factor eIF2alpha, a mechanism proposed to mediate the post-transcriptional upregulation of BACE1, was significantly elevated in STZ-treated 5XFAD mice. Meanwhile, levels of GGA3, an adapter protein responsible for sorting BACE1 to lysosomal degradation, are indistinguishable between STZ- and vehicle-treated 5XFAD mice. Moreover, STZ treatments did not affect levels of Abeta-degrading enzymes such as neprilysin and insulin-degrading enzyme (IDE) in 5XFAD brains. Taken together, our findings provide a mechanistic foundation for a link between diabetes and AD by demonstrating that insulin deficiency may change APP processing to favor beta-amyloidogenesis via the translational upregulation of BACE1 in combination with elevations in its substrate, APP.

Recently, we had the opportunity to review the progress that has been made in the field of cardiovascular disease over the past century in The FASEB Journal and, based on those thoughts, in this article we predict what may transpire inthis 'century of biology'. Although it is true that 'the best way to predict the future is to invent it', we gaze through the prism of modern biomolecular science for a vision of a possible future and see cardiology practice that is transformed. In the second half of the 20th century, we developed a more fundamental understanding of atherosclerotic vascular disorders and invented life-saving therapeutics. We saw a similar development of mechanism-based pharmacotherapy to address heart failure, primarily through agents that antagonize the excessive concentration of circulating neurohumoral agents. Now we are in the midst of the device era, from stents to cardiac resynchronization therapy to transcatheter valves.The next wave of treatments will build on an increasingly sophisticated understanding of the molecular determinants of cardiovascular disorders and engineering feats that are barely perceptible now. Genomic profiling, molecular prescriptions for prevention and personalized therapeutics, regenerative medicine and the new field of cardiovascular tissue bioengineering will transform cardiovascular medicine. If the human species can survive threats of our own doing, such as the related epidemics of obesity and diabetes, by the turn of the next century, treatment of cardiovascular disease will not resemble the present in almost any way. Touch Medical Media 2012

PURPOSE: To acquire and characterize cellular-resolved in vivo fluorescence images of optogenetic probes expressed in rodent retinal ganglion cells, by adapting a low-cost and simple fundus system based on a topical endoscope. METHODS: A custom endoscope-based fundus system was constructed (adapted from the design of Paques and colleagues). Bright field and fluorescence images were acquired from head-fixed transgenic mice expressing Channelrhodopsin2-eYFP, and Sprague Dawley rats virally transfected with the optogenetic probe GCaMP3. Images were compared to in vitro images of the same structures and were analyzed. RESULTS: The fundus system provides high-quality, high-resolution fluorescence images of the eye fundus that span the whole retina. The images allow resolving individual cells and axon bundles in the Channelrhodopsin2-eYFP mice and cellular-scale structures in the GCaMP3 expressing rats. The resolution in mouse eyes was estimated to be better than 20 mum (full width at half maximum) and is only marginally dependent on movement-related blurring. CONCLUSIONS: The fluorescence-endoscopy fundus system provides a powerful yet simple and widely accessible tool for obtaining cellular resolved fluorescent images of optogenetic and other fluorescent probes. TRANSLATIONAL RELEVANCE: The new system could prove to be a basic tool for non-invasive in vivo small animal retinal imaging in a wide array of translational vision applications, including the tracking of fluorescently tagged cells and the expression of gene-therapy and optogenetic vectors.